Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
about
Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flowSolution structure of the major factor VIII binding region on von Willebrand factorWeibel-Palade bodies: a window to von Willebrand disease.Factoring in Factor VIII With Acute Ischemic StrokeA mouse model of severe von Willebrand disease: defects in hemostasis and thrombosisThe role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.Influence of ABO blood groups on primary hemostasis.A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in miceHaemophilia A and haemophilia B: molecular insightsCleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.In vivo analysis of the role of O-glycosylations of von Willebrand factor.Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.The molecular biology of von Willebrand disease.Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimerasTwo distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesionMolecular mechanisms of mild and moderate hemophilia A.Crucial role for the VWF A1 domain in binding to type IV collagen.Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veinsExtracellular matrix proteins in hemostasis and thrombosisA sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.Correction of a murine model of von Willebrand disease by gene transfer.Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia AGenetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia AComposition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cellsFunctional factor VIII made with von Willebrand factor at high levels in transgenic milkTransgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIIICharacterization of a genetically engineered inactivation-resistant coagulation factor VIIIaEngineering Factor Viii for Hemophilia Gene Therapy.Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.Von Willebrand factor is reversibly decreased during torpor in 13-lined ground squirrels.Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicityPharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
P2860
Q24305071-7550EEEC-A324-47E1-A81D-64B17AC7017BQ27682916-829D6F0F-2711-4289-A65D-54D98B378F42Q27693255-63771BC3-759E-472B-A595-172D29A81F86Q28087052-695EF490-9194-4D03-BC8F-2F026882FF2FQ28586884-34054EC8-A640-40B6-A730-B14348EC879FQ30478277-ADA5A534-8954-489D-BC52-6F3B991B50BCQ30990023-FB98E3D6-D504-4E66-85AF-910EC1027232Q31846248-1D98332B-067C-4A2B-ACBB-39B9F490125BQ33917215-8879795E-DA95-4B0B-B7D3-D9FD8F7E4156Q33918888-5E0F0684-A0F6-4536-95DA-AA7489E21446Q34016608-DDBF4DCB-D0C8-46F0-B6FA-CFCC863AAD57Q34278082-6B6CE473-6D33-48BE-B450-250022811C6AQ34282379-D7BD5358-5B3E-42B1-8B61-4510E4F9CD6FQ34421530-720852F8-BA9F-43E5-B870-7DBB608522DEQ34468951-88086CC0-383C-4A44-8118-C0ED3549025EQ34601867-06BCCDD6-FA0B-4A35-89B9-DA1BCD3B734AQ34619713-1A6E2659-BA1F-4F45-939E-DB0A62BD9BA0Q35181733-EA175DF8-E5C6-431D-BDB9-635A7D3F24A4Q35252688-F1CFD649-FBC8-418B-9B19-63C44F7A2FDFQ35601547-F962F1EE-3F64-49F2-BC77-37746A8DB90DQ35750897-2A503CD3-98F2-467C-A4A4-6A86CF0FE114Q35762807-9FFC1555-482A-4326-9211-36BF4C285ED4Q35804461-F9AB2561-1512-4189-BB21-94A32DEEC02DQ35832756-5B9B5332-C7CE-4B40-838D-3BE69B371163Q35848737-589079F5-F307-430A-B294-B7176AA4558DQ35849850-84AFA550-FC7C-4D93-A9CA-A1E90A4F0442Q35985208-5FE6B09C-52C5-4700-974B-D7EA99A71224Q36097677-71EE72FE-42B3-4EB6-A420-7ED49760C2F8Q36216085-2F44D1F1-B88A-4320-A586-45BDB7758CC8Q36239576-893B6D62-709C-4386-919F-7A1A237EC97AQ36294629-F932390C-5CD0-4A18-AD0B-8DEF7172EBFFQ36621449-F9A3C2E2-BEDF-4323-9FEF-6B4CDA01F290Q36737263-BF422D58-19F4-4001-8ADC-0E7BB3AD8D84Q36768042-E850BC2C-8BDB-4EDA-AD2E-FDC0554759C9Q36818547-AE0435FC-C8BD-4175-9289-2C9BF471C2E7Q36950922-A31B5BD7-F802-4D28-8FD7-7CD356A5C2CEQ37077021-E06B6854-FFB9-4C0E-B9C3-27BE910D15F9Q37175593-3275E3C5-A971-41EA-8084-8A6527446116Q37609352-280493F2-1A40-4800-96A9-FDB806157CF2Q37614115-D14D22DE-6346-443E-B9AE-689429BBAFA5
P2860
Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1977
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stabilization of factor VIII i ...... with von Willebrand's disease.
@en
Stabilization of factor VIII i ...... with von Willebrand's disease.
@nl
type
label
Stabilization of factor VIII i ...... with von Willebrand's disease.
@en
Stabilization of factor VIII i ...... with von Willebrand's disease.
@nl
prefLabel
Stabilization of factor VIII i ...... with von Willebrand's disease.
@en
Stabilization of factor VIII i ...... with von Willebrand's disease.
@nl
P2093
P2860
P356
P1476
Stabilization of factor VIII i ...... with von Willebrand's disease.
@en
P2093
P2860
P304
P356
10.1172/JCI108788
P407
P577
1977-08-01T00:00:00Z